Home
ENLV

ENLV

Enlivex Therapeutics Ltd.

as of 12-05-2025 3:41pm EST

$1.24

+$0.08

+7.11%

Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Chart Type:

Time Range:

Founded:	2005	Country:	Israel
Employees:	N/A	City:	N/A
Market Cap:	26.6M	IPO Year:	1995
Target Price:	$7.00	AVG Volume (30 days):	11.3M
Analyst Decision:	Buy	Number of Analysts:	2
Dividend Yield:	N/A	Dividend Payout Frequency:	N/A
EPS:	-0.54	EPS Growth:	N/A
52 Week Low/High:	$0.83 - $2.10	Next Earning Date:	11-28-2025
Revenue:	N/A	Revenue Growth:	N/A
Revenue Growth (this year):	N/A	Revenue Growth (next year):	N/A

AI-Powered ENLV Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 3 days ago

AI Recommendation

hold

Model Accuracy: 73.79%

73.79%

Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

View Full ENLV Forecast & Prediction with Hourly Data

Compare ENLV vs Leading Stocks

See how ENLV stacks up against similar companies in the market

Share on Social Networks:

Tools & Resources

Enhance your trading experience with our free tools

Free ENLV Stock Widget

Embed our interactive stock ticker widget on your website for real-time updates.

Free Tool

Stock Alerts on Telegram

Get instant notifications, market insights, and expert analysis delivered to your phone.

Live Updates

Disclaimer

The information presented on this page, "ENLV Enlivex Therapeutics Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.